{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:46:50Z","timestamp":1789051610858,"version":"build-2803163510"},"reference-count":107,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Diagnostic Pathology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1053\/j.semdp.2020.12.001","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T12:01:56Z","timestamp":1607083316000},"page":"193-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary\u2730"],"prefix":"10.1053","volume":"38","author":[{"given":"Josephine K.","family":"Dermawan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1053\/j.semdp.2020.12.001_bib0001","doi-asserted-by":"crossref","first-page":"v133","DOI":"10.1093\/annonc\/mdv305","article-title":"Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Fizazi","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1053\/j.semdp.2020.12.001_bib0002","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s41416-019-0723-z","article-title":"Exploring the biological hallmarks of cancer of unknown primary: where do we stand today?","volume":"122","author":"Rassy","year":"2020","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1053\/j.semdp.2020.12.001_bib0003","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.semdp.2017.11.013","article-title":"Diagnosis and management of metastatic neoplasms with unknown primary","volume":"35","author":"Bochtler","year":"2018","journal-title":"Semin Diagn Pathol"},{"issue":"9824","key":"10.1053\/j.semdp.2020.12.001_bib0004","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(11)61178-1","article-title":"Cancer of unknown primary site","volume":"379","author":"Pavlidis","year":"2012","journal-title":"Lancet"},{"issue":"9","key":"10.1053\/j.semdp.2020.12.001_bib0005","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1002\/cam4.1689","article-title":"Cancer of unknown primary\u2014Epidemiological trends and relevance of comprehensive genomic profiling","volume":"7","author":"Binder","year":"2018","journal-title":"Cancer Med"},{"key":"10.1053\/j.semdp.2020.12.001_bib0006","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.canep.2019.06.006","article-title":"The currently declining incidence of cancer of unknown primary","volume":"61","author":"Rassy","year":"2019","journal-title":"Cancer Epidemiol"},{"issue":"9","key":"10.1053\/j.semdp.2020.12.001_bib0007","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1002\/cncr.21833","article-title":"The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study","volume":"106","author":"Seve","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"10.1053\/j.semdp.2020.12.001_bib0008","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ctrv.2008.10.003","article-title":"Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review","volume":"35","author":"Pentheroudakis","year":"2009","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1053\/j.semdp.2020.12.001_bib0009","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/annonc\/mdr536","article-title":"Survival in cancer of unknown primary site: population-based analysis by site and histology","volume":"23","author":"Hemminki","year":"2012","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1053\/j.semdp.2020.12.001_bib0010","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3747\/co.25.4003","article-title":"Survival outcome differences based on treatments used and knowledge of the primary tumour site for patients with cancer of unknown and known primary in Ontario","volume":"25","author":"Kim","year":"2018","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1053\/j.semdp.2020.12.001_bib0011","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12885-017-3083-1","article-title":"Cancers of unknown primary diagnosed during hospitalization: a population-based study","volume":"17","author":"Jones","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1053\/j.semdp.2020.12.001_bib0012","first-page":"10","article-title":"Progress in refining the clinical management of cancer of unknown primary in the molecular era","author":"Rassy","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.semdp.2020.12.001_bib0013","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.3389\/fonc.2019.01546","article-title":"Metastatic Cancer of Unknown Primary\" or \"Primary Metastatic Cancer\"?","volume":"9","author":"Kolling","year":"2020","journal-title":"Front Oncol"},{"issue":"2","key":"10.1053\/j.semdp.2020.12.001_bib0014","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0277-5379(85)90171-3","article-title":"Metastatic adenocarcinoma of unknown primary site: abnormalities of cellular DNA content and survival","volume":"21","author":"Hedley","year":"1985","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"1","key":"10.1053\/j.semdp.2020.12.001_bib0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1476-5586(03)80014-3","article-title":"Cytogenetic profile of unknown primary tumors: clues for their pathogenesis and clinical management","volume":"5","author":"Pantou","year":"2003","journal-title":"Neoplasia"},{"key":"10.1053\/j.semdp.2020.12.001_bib0016","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12885-015-1128-x","article-title":"Cancers of unknown primary origin (CUP) are characterized by chromosomal instability (CIN) compared to metastasis of known origin","volume":"15","author":"Vikes\u00e5","year":"2015","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1053\/j.semdp.2020.12.001_bib0017","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2000.18.3.632","article-title":"Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site","volume":"18","author":"Hainsworth","year":"2000","journal-title":"J Clin Oncol"},{"issue":"6B","key":"10.1053\/j.semdp.2020.12.001_bib0018","first-page":"2563","article-title":"Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin","volume":"15","author":"Pavlidis","year":"1995","journal-title":"Anticancer Res"},{"issue":"7","key":"10.1053\/j.semdp.2020.12.001_bib0019","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/sj.bjc.6603942","article-title":"Carcinoma of an unknown primary: are EGF receptor, Her-2\/neu, and c-Kit tyrosine kinases potential targets for therapy","volume":"97","author":"Massard","year":"2007","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1053\/j.semdp.2020.12.001_bib0020","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/annonc\/mds097","article-title":"Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP cases","volume":"23","author":"Golfinopoulos","year":"2012","journal-title":"Ann Oncol"},{"issue":"3B","key":"10.1053\/j.semdp.2020.12.001_bib0021","first-page":"1907","article-title":"Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study","volume":"18","author":"Briasoulis","year":"1998","journal-title":"Anticancer Res"},{"issue":"5A","key":"10.1053\/j.semdp.2020.12.001_bib0022","first-page":"1619","article-title":"p53 gene mutation spectrum in human unknown primary tumors","volume":"13","author":"Bar-Eli","year":"1993","journal-title":"Anticancer Res"},{"key":"10.1053\/j.semdp.2020.12.001_bib0023","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2407-5-25","article-title":"Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1","volume":"5","author":"Karavasilis","year":"2005","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1053\/j.semdp.2020.12.001_bib0024","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1002\/cncr.21454","article-title":"Matrix metalloproteinases in carcinoma of unknown primary","volume":"104","author":"Karavasilis","year":"2005","journal-title":"Cancer"},{"issue":"16","key":"10.1053\/j.semdp.2020.12.001_bib0025","doi-asserted-by":"crossref","first-page":"22140","DOI":"10.18632\/oncotarget.7903","article-title":"Germline genetics of cancer of unknown primary (CUP) and its specific subtypes","volume":"7","author":"Hemminki","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1053\/j.semdp.2020.12.001_bib0026","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1001\/jamaoncol.2015.4265","article-title":"Familial risk in patients with carcinoma of unknown primary","volume":"2","author":"Samadder","year":"2016","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1053\/j.semdp.2020.12.001_bib0027","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.7150\/jca.42880","article-title":"Cancer of unknown primary site: real entity or misdiagnosed disease?","volume":"11","author":"Alshareeda","year":"2020","journal-title":"J Cancer"},{"key":"10.1053\/j.semdp.2020.12.001_bib0028","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fonc.2019.00402","article-title":"Does Cancer Of Unknown Primary (CUP) truly exist as a distinct cancer entity?","volume":"9","author":"Bochtler","year":"2019","journal-title":"Front Oncol"},{"issue":"4","key":"10.1053\/j.semdp.2020.12.001_bib0029","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1634\/theoncologist.12-4-418","article-title":"Cancer of unknown primary site: missing primary or missing biology?","volume":"12","author":"Pentheroudakis","year":"2007","journal-title":"Oncologist"},{"issue":"4","key":"10.1053\/j.semdp.2020.12.001_bib0030","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10585-012-9548-3","article-title":"Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors","volume":"30","author":"Pentheroudakis","year":"2013","journal-title":"Clin Exp Metastasis"},{"issue":"2","key":"10.1053\/j.semdp.2020.12.001_bib0031","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5858\/134.2.216","article-title":"Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin","volume":"134","author":"Monzon","year":"2010","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1053\/j.semdp.2020.12.001_bib0032","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/nar\/30.1.207","article-title":"Gene Expression Omnibus: NCBI gene expression and hybridization array data repository","volume":"30","author":"Edgar","year":"2002","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"10.1053\/j.semdp.2020.12.001_bib0033","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The cancer genome atlas pan-cancer analysis project","volume":"45","author":"JN","year":"2013","journal-title":"Nat Genet"},{"issue":"Database issue","key":"10.1053\/j.semdp.2020.12.001_bib0034","doi-asserted-by":"crossref","first-page":"D553","DOI":"10.1093\/nar\/gki056","article-title":"ArrayExpress\u2013a public repository for microarray gene expression data at the EBI","volume":"33","author":"Parkinson","year":"2005","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1053\/j.semdp.2020.12.001_bib0035","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/j.seminoncol.2008.10.002","article-title":"Molecular classification of unknown primary cancer","volume":"36","author":"Bender","year":"2009","journal-title":"Semin Oncol"},{"issue":"4","key":"10.1053\/j.semdp.2020.12.001_bib0036","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00428-014-1545-2","article-title":"Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care","volume":"464","author":"Hainsworth","year":"2014","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1053\/j.semdp.2020.12.001_bib0037","doi-asserted-by":"crossref","DOI":"10.1515\/jib-2017-0013","article-title":"Prediction of primary tumors in cancers of unknown primary","volume":"14","author":"S\u00f8ndergaard","year":"2017","journal-title":"J Integr Bioinform"},{"issue":"27","key":"10.1053\/j.semdp.2020.12.001_bib0038","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1200\/JCO.2007.14.4378","article-title":"Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation","volume":"26","author":"Varadhachary","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1053\/j.semdp.2020.12.001_bib0039","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1158\/0008-5472.CAN-04-3617","article-title":"An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin","volume":"65","author":"Tothill","year":"2005","journal-title":"Cancer Res"},{"issue":"7","key":"10.1053\/j.semdp.2020.12.001_bib0040","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/jclinpath-2017-204887","article-title":"An integrated tool for determining the primary origin site of metastatic tumours","volume":"71","author":"Santos","year":"2018","journal-title":"J Clin Pathol"},{"issue":"1","key":"10.1053\/j.semdp.2020.12.001_bib0041","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s12967-019-2082-1","article-title":"90-gene signature assay for tissue origin diagnosis of brain metastases","volume":"17","author":"Zheng","year":"2019","journal-title":"J Transl Med"},{"issue":"11","key":"10.1053\/j.semdp.2020.12.001_bib0042","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jnci\/djt099","article-title":"Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology","volume":"105","author":"Greco","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1053\/j.semdp.2020.12.001_bib0043","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40291-015-0133-8","article-title":"Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay","volume":"19","author":"Greco","year":"2015","journal-title":"Mol Diagn Ther"},{"issue":"14","key":"10.1053\/j.semdp.2020.12.001_bib0044","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1158\/1078-0432.CCR-12-0920","article-title":"Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier","volume":"18","author":"Kerr","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.semdp.2020.12.001_bib0045","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/modpathol.2013.105","article-title":"A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors","volume":"27","author":"Kerr","year":"2014","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1053\/j.semdp.2020.12.001_bib0046","doi-asserted-by":"crossref","first-page":"e713","DOI":"10.1016\/j.clgc.2016.11.004","article-title":"Role of molecular profiling in diagnosis of papillary renal-cell cancer presenting as cancer of unknown primary site","volume":"15","author":"Nagasaka","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1053\/j.semdp.2020.12.001_bib0047","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1746-1596-5-3","article-title":"Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test","volume":"5","author":"Monzon","year":"2010","journal-title":"Diagn Pathol"},{"issue":"7","key":"10.1053\/j.semdp.2020.12.001_bib0048","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1097\/PAS.0b013e3182178b59","article-title":"Evaluation of a gene expression microarray-based assay to determine tissue type of origin on a diverse set of 49 malignancies","volume":"35","author":"Beck","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1053\/j.semdp.2020.12.001_bib0049","doi-asserted-by":"crossref","first-page":"e63249","DOI":"10.1371\/journal.pone.0063249","article-title":"A microarray-based gene expression analysis to identify diagnostic biomarkers for unknown primary cancer","volume":"8","author":"Kurahashi","year":"2013","journal-title":"PLoS ONE"},{"issue":"27","key":"10.1053\/j.semdp.2020.12.001_bib0050","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1200\/JCO.2007.14.6969","article-title":"Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary","volume":"26","author":"Horlings","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.semdp.2020.12.001_bib0051","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/cncy.20167","article-title":"Identification of tissue of origin in body fluid specimens using a gene expression microarray assay","volume":"120","author":"Stancel","year":"2012","journal-title":"Cancer Cytopathol"},{"issue":"1","key":"10.1053\/j.semdp.2020.12.001_bib0052","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/PAT.0000000000000194","article-title":"Development and validation of a gene expression tumour classifier for cancer of unknown primary","volume":"47","author":"Tothill","year":"2015","journal-title":"Pathology"},{"issue":"6","key":"10.1053\/j.semdp.2020.12.001_bib0053","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1309\/AJCPDQPFO73SSNFR","article-title":"Clinical verification of the performance of the pathwork tissue of origin test: utility and limitations","volume":"136","author":"Dumur","year":"2011","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"10.1053\/j.semdp.2020.12.001_bib0054","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/PAS.0b013e31828309c4","article-title":"A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors","volume":"37","author":"Handorf","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.semdp.2020.12.001_bib0055","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1746-1596-7-110","article-title":"Comparison of histopathology to gene expression profiling for the diagnosis of metastatic cancer","volume":"7","author":"Kulkarni","year":"2012","journal-title":"Diagn Pathol"},{"key":"10.1053\/j.semdp.2020.12.001_bib0056","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1746-1596-5-26","article-title":"Gene expression profiles help identify the tissue of origin for metastatic brain cancers","volume":"5","author":"Wu","year":"2010","journal-title":"Diagn Pathol"},{"issue":"11","key":"10.1053\/j.semdp.2020.12.001_bib0057","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.neo.2014.09.007","article-title":"RNA-Seq accurately identifies cancer biomarker signatures to distinguish tissue of origin","volume":"16","author":"Wei","year":"2014","journal-title":"Neoplasia"},{"issue":"6","key":"10.1053\/j.semdp.2020.12.001_bib0058","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/modpathol.2016.60","article-title":"Pan-cancer transcriptome analysis reveals a gene expression signature for the identification of tumor tissue origin","volume":"29","author":"Xu","year":"2016","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1053\/j.semdp.2020.12.001_bib0059","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2597","article-title":"Application of a neural network whole transcriptome-based pan-cancer method for diagnosis of primary and metastatic cancers","volume":"2","author":"Grewal","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1053\/j.semdp.2020.12.001_bib0060","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s13258-018-0773-2","article-title":"Identification of tissue-specific tumor biomarker using different optimization algorithms","volume":"41","author":"Bhowmick","year":"2019","journal-title":"Genes Genomics"},{"key":"10.1053\/j.semdp.2020.12.001_bib0061","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3389\/fbioe.2020.00394","article-title":"TOOme: a novel computational framework to infer cancer tissue-of-origin by integrating both gene mutation and expression","volume":"8","author":"He","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"issue":"6","key":"10.1053\/j.semdp.2020.12.001_bib0062","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/modpathol.2010.57","article-title":"Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin","volume":"23","author":"Rosenwald","year":"2010","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1053\/j.semdp.2020.12.001_bib0063","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jmoldx.2013.10.001","article-title":"Efficient identification of miRNAs for classification of tumor origin","volume":"16","author":"S\u00f8kilde","year":"2014","journal-title":"J Mol Diagn"},{"key":"10.1053\/j.semdp.2020.12.001_bib0064","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1476-4598-12-57","article-title":"Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary","volume":"12","author":"Pentheroudakis","year":"2013","journal-title":"Mol Cancer"},{"issue":"6","key":"10.1053\/j.semdp.2020.12.001_bib0065","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1634\/theoncologist.2011-0466","article-title":"A second-generation microRNA-based assay for diagnosing tumor tissue origin","volume":"17","author":"Meiri","year":"2012","journal-title":"Oncologist"},{"issue":"12","key":"10.1053\/j.semdp.2020.12.001_bib0066","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1158\/1078-0432.CCR-10-2599","article-title":"Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary","volume":"17","author":"Varadhachary","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"7300","key":"10.1053\/j.semdp.2020.12.001_bib0067","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/nature09167","article-title":"International network of cancer genome projects","volume":"465","author":"TJ","year":"2010","journal-title":"Nature"},{"issue":"7484","key":"10.1053\/j.semdp.2020.12.001_bib0068","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature12912","article-title":"Discovery and saturation analysis of cancer genes across 21 tumor types","volume":"505","author":"Lawrence","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1053\/j.semdp.2020.12.001_bib0069","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1186\/s12885-019-5677-2","article-title":"Portrait of a cancer: mutational signature analyses for cancer diagnostics","volume":"19","author":"Van Hoeck","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1053\/j.semdp.2020.12.001_bib0070","doi-asserted-by":"crossref","first-page":"16927","DOI":"10.1038\/s41598-019-53034-3","article-title":"CPEM: accurate cancer type classification based on somatic alterations using an ensemble of a random forest and a deep neural network","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1053\/j.semdp.2020.12.001_bib0071","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41467-019-13825-8","article-title":"A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns","volume":"11","author":"Jiao","year":"2020","journal-title":"Nat Commun"},{"issue":"4","key":"10.1053\/j.semdp.2020.12.001_bib0072","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1006953","article-title":"Passenger mutations accurately classify human tumors","volume":"15","author":"Salvadores","year":"2019","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"10.1053\/j.semdp.2020.12.001_bib0073","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/jamaoncol.2019.3985","article-title":"Development of genome-derived tumor type prediction to inform clinical cancer care","volume":"6","author":"Penson","year":"2019","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1053\/j.semdp.2020.12.001_bib0074","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/path.4251","article-title":"Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary","volume":"231","author":"Tothill","year":"2013","journal-title":"J Pathol"},{"key":"10.1053\/j.semdp.2020.12.001_bib0075","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12920-015-0130-0","article-title":"TumorTracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimen","volume":"8","author":"Marquard","year":"2015","journal-title":"BMC Med Genomics"},{"issue":"3","key":"10.1053\/j.semdp.2020.12.001_bib0076","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"issue":"11","key":"10.1053\/j.semdp.2020.12.001_bib0077","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"6","key":"10.1053\/j.semdp.2020.12.001_bib0078","doi-asserted-by":"crossref","first-page":"677","DOI":"10.6004\/jnccn.2018.7012","article-title":"Integrated histogenetic analysis reveals bap1-mutated epithelioid mesothelioma in a patient with cancer of unknown primary","volume":"16","author":"Bochtler","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1053\/j.semdp.2020.12.001_bib0079","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-212685","article-title":"Genomic characterisation of two cancers of unknown primary cases supports a kidney cancer origin","author":"Wei","year":"2015","journal-title":"BMJ Case Rep"},{"issue":"7","key":"10.1053\/j.semdp.2020.12.001_bib0080","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1634\/theoncologist.2019-0798","article-title":"Molecular profiles of brain and pulmonary metastatic disease in cancer of unknown primary","volume":"25","author":"Bakow","year":"2020","journal-title":"Oncologist"},{"issue":"11","key":"10.1053\/j.semdp.2020.12.001_bib0081","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1002\/ijc.32316","article-title":"Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome","volume":"145","author":"Bochtler","year":"2019","journal-title":"Int J Cancer"},{"issue":"7697","key":"10.1053\/j.semdp.2020.12.001_bib0082","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"issue":"15","key":"10.1053\/j.semdp.2020.12.001_bib0083","doi-asserted-by":"crossref","first-page":"8681","DOI":"10.1073\/pnas.96.15.8681","article-title":"CpG island methylator phenotype in colorectal cancer","volume":"96","author":"Toyota","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1053\/j.semdp.2020.12.001_bib0084","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(16)30297-2","article-title":"Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis","volume":"17","author":"Moran","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1053\/j.semdp.2020.12.001_bib0085","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1101\/gr.119867.110","article-title":"A DNA methylation fingerprint of 1628 human samples","volume":"22","author":"Fernandez","year":"2012","journal-title":"Genome Res"},{"issue":"10","key":"10.1053\/j.semdp.2020.12.001_bib0086","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1210\/clinem\/dgaa477","article-title":"Distinct DNA methylation signatures in neuroendocrine tumors specific for primary site and inherited predisposition","volume":"105","author":"Tirosh","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1053\/j.semdp.2020.12.001_bib0087","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nrclinonc.2017.97","article-title":"Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary","volume":"14","author":"Moran","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.semdp.2020.12.001_bib0088","doi-asserted-by":"crossref","DOI":"10.1177\/1176935119872163","article-title":"Hierarchical classification of cancers of unknown primary using multi-omics data","volume":"18","author":"Bavafaye Haghighi","year":"2019","journal-title":"Cancer Inform"},{"key":"10.1053\/j.semdp.2020.12.001_bib0089","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fonc.2020.00533","article-title":"The quest for improving treatment of cancer of unknown primary (cup) through molecularly-driven treatments: a systematic review","volume":"10","author":"Lombardo","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1053\/j.semdp.2020.12.001_bib0090","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2014.216","article-title":"Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies","volume":"1","author":"Ross","year":"2015","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1053\/j.semdp.2020.12.001_bib0091","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12967-018-1564-x","article-title":"Genetic characterisation of molecular targets in carcinoma of unknown primary","volume":"16","author":"Clynick","year":"2018","journal-title":"J Transl Med"},{"issue":"28","key":"10.1053\/j.semdp.2020.12.001_bib0092","doi-asserted-by":"crossref","first-page":"44322","DOI":"10.18632\/oncotarget.10035","article-title":"Molecular driver alterations and their clinical relevance in cancer of unknown primary site","volume":"7","author":"L\u00f6ffler","year":"2016","journal-title":"Oncotarget"},{"issue":"23","key":"10.1053\/j.semdp.2020.12.001_bib0093","doi-asserted-by":"crossref","first-page":"12440","DOI":"10.18632\/oncotarget.2574","article-title":"Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases","volume":"5","author":"Gatalica","year":"2014","journal-title":"Oncotarget"},{"issue":"6","key":"10.1053\/j.semdp.2020.12.001_bib0094","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a001180","article-title":"Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification","volume":"2","author":"Gr\u00f6schel","year":"2016","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"12","key":"10.1053\/j.semdp.2020.12.001_bib0095","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1093\/annonc\/mdx545","article-title":"Clinical and molecular characterization of patients with cancer of unknown primary in the modern era","volume":"28","author":"Varghese","year":"2017","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1053\/j.semdp.2020.12.001_bib0096","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1200\/JCO.2012.44.3937","article-title":"Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary","volume":"31","author":"Tan","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.semdp.2020.12.001_bib0097","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ygyno.2018.07.013","article-title":"Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials","volume":"150","author":"Meagher","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1053\/j.semdp.2020.12.001_bib0098","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/jamaoncol.2015.1313","article-title":"Whole-exome sequencing of metastatic cancer and biomarkers of treatment response","volume":"1","author":"Beltran","year":"2015","journal-title":"JAMA Oncol"},{"issue":"16","key":"10.1053\/j.semdp.2020.12.001_bib0099","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1158\/0008-5472.CAN-17-0628","article-title":"Utility of genomic analysis in circulating tumor DNA from patients with carcinoma of unknown primary","volume":"77","author":"Kato","year":"2017","journal-title":"Cancer Res"},{"key":"10.1053\/j.semdp.2020.12.001_bib0100","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2018.09.035","article-title":"Liquid biopsy: a new diagnostic, predictive and prognostic window in cancers of unknown primary","volume":"105","author":"Rassy","year":"2018","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1053\/j.semdp.2020.12.001_bib0101","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41416-018-0332-2","article-title":"Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the \u2018U\u2019 out of \u2018CUP\u2019","volume":"120","author":"Conway","year":"2019","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1053\/j.semdp.2020.12.001_bib0102","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/JCO.2012.43.3755","article-title":"Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute","volume":"31","author":"Hainsworth","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.semdp.2020.12.001_bib0103","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdv543","article-title":"Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance)","volume":"27","author":"Yoon","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1053\/j.semdp.2020.12.001_bib0104","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.18.00771","article-title":"Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site","volume":"37","author":"Hayashi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1053\/j.semdp.2020.12.001_bib0105","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Le Tourneau","year":"2015","journal-title":"Lancet Oncol"},{"issue":"Suppl 5","key":"10.1053\/j.semdp.2020.12.001_bib0106","doi-asserted-by":"crossref","first-page":"v851","DOI":"10.1093\/annonc\/mdz394","article-title":"A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04) [abstract LBA15_PR]","volume":"30","author":"Fizazi","year":"2019","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1053\/j.semdp.2020.12.001_bib0107","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.ejca.2007.06.023","article-title":"Switching benchmarks in cancer of unknown primary: from autopsy to microarray","volume":"43","author":"Pentheroudakis","year":"2007","journal-title":"Eur J Cancer"}],"container-title":["Seminars in Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257020301003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257020301003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:23:13Z","timestamp":1760037793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740257020301003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":107,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0740257020301003"],"URL":"https:\/\/doi.org\/10.1053\/j.semdp.2020.12.001","relation":{},"ISSN":["0740-2570"],"issn-type":[{"value":"0740-2570","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary\u2730","name":"articletitle","label":"Article Title"},{"value":"Seminars in Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semdp.2020.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}